All articles tagged with #esmo
Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.
The European Society for Medical Oncology (ESMO) Congress 2023 has experienced an embargo breach, revealing promising therapies for non-small cell lung cancer (NSCLC). Bristol Myers Squibb's Opdivo demonstrated positive results in two Phase III studies, showing a reduction in disease recurrence and improved survival rates. Mirati's adagrasib, when combined with Keytruda, showed strong first-line promise in NSCLC patients. BeiGene's tislelizumab, in combination with chemotherapy, achieved a major pathological response in a Phase III trial. Johnson & Johnson's Rybrevant-lazertinib combination demonstrated potential as a new standard of care for EGFR-mutated NSCLC. These findings will be presented at the ESMO Congress in October.
The European Society for Medical Oncology (ESMO) has released data from high-profile presentations several days early due to a broken embargo on the abstracts. The decision was made to ensure fair and equitable access to the data for all relevant parties. The release includes data from Bristol Myers, J&J, Novartis, and AstraZeneca.